Clopidogrel Tablet
Product Images NDC 52605-082

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 52605-082). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Polygen Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Clopidogrel-300mg-30s (Clopidogrel 300mg 30s)

Each film-coated tablet contains 391.5 mg of clopidogrel bisulphate, USP equivalent to 300 mg of clopidogrel. This medication requires a prescription and should be dispensed in a tight, light-resistant container. The container is child-resistant and should be stored at 20°C to 25°C (68°F to 77°F) with permitted excursions between 15°C to 30°C (59°F to 86°F) according to USP Controlled Room Temperature standards. Manufactured by Polygen Pharmaceuticals Inc, this package contains 30 tablets with the National Drug Code 52605-083-13.*

FDA Label Image

Clopidogrel-300mg-500s (Clopidogrel 300mg 500s)

Each film-coated tablet contains 391.5 mg of clopidogrel bisulphate, equivalent to 300 mg of clopidogrel. It is dispensed in a tight light-resistant container and must be stored at 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F), as stated in the USP Controlled Room Temperature. It's to be dispensed with the accompanying prescribing information and medication guide, and the container should be kept tightly closed. Polygen Pharmaceuticals Inc. in Edgewood, NY 11717 manufactured it. The product has 500 tablets, and the NDC is 52605-083-05.*

FDA Label Image

Clopidogrel-75mg-1000s (Clopidogrel 75mg 1000s)

This is a medication description for tablets containing 97.875mg of clopidogrel bisulphate, equivalent to 75mg of clopidogrel. The usual dosage information is not available, but it is advised to dispense the medication in a tight, light-resistant container and keep it tightly closed. The tablets should be stored at a temperature between 20°C to 25°C, with excursion permitted between 15°C to 30°C. The manufacturer of the tablets is Polygen Pharmaceuticals Inc. A Medication Guide should be dispensed to each patient.*

FDA Label Image

Clopidogrel-75mg-30s (Clopidogrel 75mg 30s)

FDA Label Image

Fig1 (Clopidogrel Figure1)

This is a table showing the effect of co-administering different drugs on the active metabolite AUC (area under the curve), with their mean and 90% confidence interval. The drugs listed are Dexlansoprazole (60mg), Lansoprazole (30mg), Pantoprazole (80mg), and Omeprazole (80mg). There is some additional non-textual characters present in the text that do not represent any language, hence have been ignored.*

FDA Label Image

Fig2 (Clopidogrel Figure2)

This is a chart showing the cumulative event rate of cardiovascular death, myocardial infarction, and stroke for patients taking a placebo with aspirin versus those taking clopidogrel tablets with aspirin. The chart indicates that the clopidogrel tablets had a notably lower event rate. The chart includes 12 months of follow-up and notes that other standard therapies were used as appropriate.*

FDA Label Image

Fig3-ctd (Clopidogrel Figure3 Ctd)

FDA Label Image

Fig3 (Clopidogrel Figure3)

This appears to be a table with statistical data regarding the effects of Clopidogrel versus Placebo on a variety of demographic and health factors such as age, gender, race, and medical history. The table includes subgroup numbers and expected values on a number of variables, as well as a hazard ratio. It is not entirely clear what the overall study was examining or what the findings were, but it appears to be a medical or pharmaceutical study.*

FDA Label Image

Fig4 (Clopidogrel Figure4)

The text describes a comparison between the placebo and Clopidogrel treatments over a period of 28 days. The treatments were compared based on the proportional risk reduction of deaths, with Clopidogrel showing a 7% reduction compared to the placebo. The data is presented on a graph with days since randomization on the X-axis and the proportional risk reduction on the Y-axis.*

FDA Label Image

Fig5 (Clopidogrel Figure5)

This text describes the results of a study comparing the efficacy of a drug called Clopidogrel with a placebo in reducing the risk of death, reinfarction, or stroke before discharge. The study involved 2310 people who received a placebo and 2121 people who received Clopidogrel. The percentage of people who experienced an event was lower in the Clopidogrel group (9.2%) compared to the placebo group (10.1%). The study found a 9% proportional risk reduction and a p-value of 0.002. The study lasted up to 28 days and all patients received aspci.*

FDA Label Image

Fig6 (Clopidogrel Figure6)

This is a statistical table with information on subgroups, including gender, age at entry, hours since onset, blood pressure, heart rate, and whether the participant received fibrinolytic agent, clopidogrel or a placebo. The table has odds ratio values included but no information on what they represent.*

FDA Label Image

Fig7 (Clopidogrel Figure7)

The text represents a chart that shows the cumulative event rate (in percentage) of fatal or non-fatal vascular events with Aspirin and Clopidogrel tablets over a follow-up period of 6,12 and 18 months, respectively. The chart indicates that Clopidogrel tablets have a lower cumulative event rate compared to Aspirin. Additionally, the chart suggests that the difference between the two is considered statistically significant with a P-value of 0.045.*

FDA Label Image

Fig8 (Clopidogrel Figure8)

FDA Label Image

Clopidogrel-structure (Clopidogrel Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.